Allergan, the pharmaceutical company known for making a popular brand of botulinum toxin injectable, hyaluronic acid-based fillers, and CoolSculpting Elite, continues to shape the future of the aesthetics industry with its dedication to innovation and research through AbbVie’s BeBold Study.
Cutis is thrilled to be chosen as a global participant in this landmark study, intended to investigate the long-term safety, efficacy, and patient satisfaction associated with repeated onabotulinumtoxinA treatments. This project is a worldwide study across 14 clinics.
Cutis’s medical and scientific director, Dr. Sylvia Ramirez, who is also a member of the Global OnabotulinumtoxinA Advisory Board, will be the principal investigator for Singapore. Our two dedicated staff, Andrea and Chooi Fan, will also serve as study coordinators for this research.
Cutis is also honored to head the approved Research Institute by the Ministry of Health Singapore. This study, furthermore, has received Ethics approval from the Parkway Independent Ethics Committee.
While aesthetic treatments are mostly seen as a way to enhance a person’s beauty, they are a blend of science and art. Aesthetic doctors and similar practitioners combine scientific knowledge with artistic skills not just to deliver impressive results, but also to have safe, effective, and lasting treatments.
This is one of the things we focus on at Cutis. Our clinic, which is based on the fundamentals of scientifically proven “evidence-based” aesthetic treatments, offers US FDA-cleared and CE-marked products and procedures. We also have a team of skilled professionals led by Dr. Sylvia Ramirez, who is a Harvard-trained physician with over 20 years of experience in medicine.
Our recent involvement in the BeBold Study further demonstrates our commitment to evidence-based aesthetic treatments. This helps ensure that we deliver safe and effective care to our patients, as well as transformative experiences that empower patient confidence.
Microneedling, which involves creating microscopic punctures in the skin to stimulate collagen, has been popular…
Cutis is thrilled to introduce VYC-12, a US FDA-approved hyaluronic acid microdroplet injectable. Indicated to…
Worried about blemishes and uneven skin tone? While a good skin care regimen can help…
The US Food and Drug Administration (FDA) has approved Allergan’s OnabotulinumtoxinA for treating moderate to…
The term “cortisol face” has created a buzz on social media (especially TikTok), with many…
On average, the skin renewal process takes about 28 days. This helps make sure that…